As low as 1:23! Announcement of the results of the central selection of 13 drugs in Hebei Province

[industry trends of pharmaceutical network] on December 19, Hebei medical drug and device Centralized Procurement Center released the list of 13 selected drugs for centralized procurement of outpatient drugs for hypertension and diabetes, which is consistent with the list of proposed winners announced on December 11, with several drugs costing only a few cents each Captopril 2:2, metformin 4:3, nitrendipine 1:9 Among them, the nifedipine tablet selected by Shandong Luxi pharmaceutical industry is no more than 1 point 23 Photo source: in fact, as early as the end of November in Hebei Province, when the centralized procurement document of drugs for urban and rural residents' hypertension diabetes outpatient service was published, and the catalog of procurement varieties, agreed procurement volume and ceiling price were given, industry analysis speculated that the price trend was similar to today's According to the policy given in the document, the purchase period is one year The winning varieties will be given to all the market shares of Hebei Province under the general name of the selected enterprises of "two diseases" outpatient drugs of urban and rural residents, and the outpatient drugs within the reimbursement scope of "two diseases" medical insurance of urban and rural residents will be subject to closed management In fact, from this publicity, the price reduction is still larger than expected in the industry It can be seen that this time, the attitude of enterprises is very obvious At present For pharmaceutical companies, especially innovative pharmaceutical companies, whether to enter the medical insurance catalog has more obvious effect on product volume Enterprises don't need to study the policies of drug purchase and purchase in different regions, as long as they can achieve the national market volume through access negotiations Therefore, the enterprise attaches great importance to it and is willing to exchange price for quantity No matter how low the price is, it is also the independent management right of the enterprise, which is the result of enterprise calculation In fact, it is becoming more and more common for pharmaceutical companies to exchange price for quantity For example, on November 12, Liaoning drug consumables centralized purchase network announced the notice on the results of gradient price reduction of drugs selected at the end of centralized drug procurement in the alliance region (Liaoning Province) A total of 180 drug independent declaration and price reduction applications from 59 drug manufacturers were received Information shows that 114 drugs from 49 pharmaceutical companies meet the price reduction requirements Earlier, Hainan public resources trading service center also issued the notice on price reduction of some drugs According to the drug price reduction application submitted by the enterprise, the center lowered the bid winning / online price of some drugs in Hainan drug trading system Among them, Chengdu Yuandong biopharmaceutical Co., Ltd applied for the price reduction of two specifications of ibuprofen injection The price of 8ml: 0.8g decreased from 180 yuan / bottle before adjustment to 97.92 yuan / bottle, a decrease of 45.5% The price of 40mg: 0.8ml decreased from 7820 yuan / bottle before price adjustment to 3160 yuan / bottle, with a decrease of 59.5% In addition, 97 drugs were selected successfully in the new round of medical insurance catalogue negotiation In terms of the products selected successfully, the average price reduction of the newly added products exceeds 60%, and some of the products exceed the expectation For example, xiumeile, the world's "king of medicine", this product's medical insurance price is 1290 yuan According to the comparison of the median national bidding price before, the price drop has reached 83.50% Obviously, at present, many pharmaceutical companies take the initiative to reduce prices, which is affected by market and policy pressure Whether it's the unselected products or the original drugs, they can't escape the fate of price reduction Some insiders said that according to the progress schedule of medical reform, many policy documents of reform are about to be issued or gradually implemented in depth In addition, the policy announcement of more regions around the reform of volume purchase and medical insurance payment mode in the future will continue to expand the impact on pharmaceutical enterprises, and more drugs that will reduce prices are still on the way.